NCT01558375.

Trial name or title	A Double‐blind, Randomized, Placebo‐controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa
Methods	This is a phase 2 placebo‐controlled trial
Participants	The trial is including adults with moderate to severe HS (Hurley stage II to III)
Interventions	Anakinra (anti‐IL‐1) 100 mg OD/placebo for 12 weeks
Outcomes	Changes in scoring parameters in a 24‐week timeframe
Starting date	March 2012 (likely finish: March 2014)
Contact information	Evangelos J Giamarellos‐Bourboulis MD, PhD (egiamarel@med.uoa.gr)
Notes	The University of Athens sponsors the trial